Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan G Pol

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Current Opinion in Gastroenterology|January 3, 2020
Immune contexture of cholangiocarcinomaJuliette Paillet, Guido Kroemer, Jonathan G Pol
Oncoimmunology|September 18, 2018
Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapiesShashi Gujar, Jonathan G Pol, Guido Kroemer
Oncoimmunology|May 30, 2024
Immunogenic oncolysis by tigilanol tiglateJonathan G Pol, Manuela Lizarralde-Guerrero, Guido Kroemer
Oncoimmunology|May 5, 2020
FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatinJonathan G Pol, Julie Le Naour, Guido Kroemer
Oncoimmunology|September 16, 2021
Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinomaJonathan G Pol, Juliette Paillet, Céleste Plantureux, et al.
Oncoimmunology|September 14, 2020
Repurposing CD8<sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?Shashi Gujar, Jonathan G Pol, Youra Kim, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 6, 2019
Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic VaccinationJonathan G Pol, Byram W Bridle, Brian D Lichty
Methods in Molecular Biology (Clifton, N.J.)|November 23, 2018
Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse ModelsJuliette Humeau, Sarah Lévesque, Guido Kroemer, et al.
Cancers|April 3, 2021
Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer ImmunotherapyErwan Eriau, Juliette Paillet, Guido Kroemer, et al.
Oncoimmunology|November 25, 2024
RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcomeJonathan G Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Current Opinion in Gastroenterology|January 3, 2020
Immune contexture of cholangiocarcinomaJuliette Paillet, Guido Kroemer, Jonathan G Pol
Oncoimmunology|September 18, 2018
Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapiesShashi Gujar, Jonathan G Pol, Guido Kroemer
Oncoimmunology|May 30, 2024
Immunogenic oncolysis by tigilanol tiglateJonathan G Pol, Manuela Lizarralde-Guerrero, Guido Kroemer
Oncoimmunology|May 5, 2020
FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatinJonathan G Pol, Julie Le Naour, Guido Kroemer
Oncoimmunology|September 16, 2021
Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinomaJonathan G Pol, Juliette Paillet, Céleste Plantureux, et al.
Oncoimmunology|September 14, 2020
Repurposing CD8<sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?Shashi Gujar, Jonathan G Pol, Youra Kim, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 6, 2019
Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic VaccinationJonathan G Pol, Byram W Bridle, Brian D Lichty
Methods in Molecular Biology (Clifton, N.J.)|November 23, 2018
Gold Standard Assessment of Immunogenic Cell Death in Oncological Mouse ModelsJuliette Humeau, Sarah Lévesque, Guido Kroemer, et al.
Cancers|April 3, 2021
Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer ImmunotherapyErwan Eriau, Juliette Paillet, Guido Kroemer, et al.
Oncoimmunology|November 25, 2024
RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcomeJonathan G Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, et al.
Pageof 6